key: cord-0857023-ri072qx0
authors: Elzein, Fatehi; Alsherbeeni, Nisreen; Almatrafi, Kholoud; Shosha, Diaa; N, Kaabia
title: COVID-19 Co-infection in a patient with brucella bacteremia
date: 2020-08-06
journal: Respir Med Case Rep
DOI: 10.1016/j.rmcr.2020.101183
sha: 0522fa36998accaccc4687d1e449818e7e0a0b6c
doc_id: 857023
cord_uid: ri072qx0

We discuss a patient who presented with fever, chills and rigors, myalgia, sore throat, diarrhea, and abdominal pain. The total white blood cell count was normal. The lymphocyte and platelet counts were within normal limits. There was no contact with confirmed COVID-19 patient, but the disease was circulating at the time of presentation. He admitted to anosmia and hypogeusia. A nasopharyngeal swab r-RT PCR test was positive for the SARS-CoV-2 virus. His chest examination and chest x-ray were normal. The patient had contact with animals and consumed unpasteurized camel milk. Both the blood culture and brucella serology tests were positive. This case illustrates that co-infection can occur and it is important to rule out endemic diseases in patients with COVID-19. Similarly, patients presenting with febrile endemic diseases may be harboring mild SARS-COV-2 virus infections and may need to be screened when the disease is suggested by epidemiological exposure.

COVID-19 was first described, following a series of pneumonia cases of unknown cause that emerged in Wuhan, Hubei, China in December 2019. The disease is caused by a bat virus like previous SARS so the name SARS-COV 2. [1] Although the initial infection was zoonotic following exposure to animals in Huanan seafood market, the virus spilled over leading to human-to human transmission with a very high infectivity rate though lower mortality than SARS and MERS -CoV infection. Most of the infections are mild or asymptomatic (81%) with sever disease occurring in 14% of the patients. Critical illness requiring ICU admission is seen in 5% of the cases. [1, 2] Severe and critical diseases are related to age, comorbid illness including hypertension, diabetes mellitus, obesity, cardiac and chronic respiratory diseases. The diagnosis is best established by nasopharyngeal swab for reverse transcriptase polymerase chain reaction (RT-PCR) assay while lower respiratory tract specimen can be tested in intubated patients. False negative tests can reach up to 33% following a single test. [3] Of note, a negative initial test in epidemiologically suspected patient does not exclude the diagnosis and should be repeated. At present, there is no established treatment for COVID-19 and drugs should be prescribed within on-going clinical trials.

A 41-year-old-man presented to clinic on 08/03/2020 with back pain, fever and dysuria. He was prescribed oral cefuroxime 500mg twice daily and paracetamol tablets. One week later he presented with extreme fatigue but no fever. The white cell count (WBC) was 5.810 9 /L, lymphocytes were normal at 2.310 9 /L, and hemoglobin was 12.3 g/dL. Renal, hepatic function and ferritin were normal. On the 18/03/2020 he attended the emergency department with a history of fever, chest pain, worsening fatigue, sore throat, runny nose, muscle and joint pain and diarrhea. He also complained of anorexia and loss of taste. The WBC was 5.6 x 10 9 /L, Our patient presented with symptoms that were suggestive of both brucellosis and COVID-19 disease, including high-grade fever, chills and rigors, fatigue, myalgia, and joint pains. However, a history of rhinorrhea, sore throat diarrhea, and extreme fatigue are more commonly reported with COVID-19. In contrast, respiratory involvement in brucellosis is infrequent and is mainly described in case reports. [4] Furthermore, diarrhea is more common in SARS-2 infections, whereas drenching sweating is typical for brucellosis. [5] In a report of 1,482 hospitalized patients with confirmed COVID-19 in the United States, diarrhea and nausea were reported in 27% and 24% of patients, respectively. [6] In addition, our case presented with a loss of taste, which is more peculiar to SARS-CoV-2 and not usually reported in brucellosis. In a multicenter European study of 417 patients with mild to moderate illness, 86% of the patients reported High rates of co-infection between SARS-CoV-2 and other respiratory pathogens has been described, including influenza, legionnaire disease, dengue virus, and mycoplasma pneumonia. [12] [13] [14] [15] Importantly, the presence of other pathogens, particularly respiratory viruses, should not be taken as evidence that a patient does not also harbor a SARS-CoV-2 coinfection. [16] To the best of our knowledge, this is the first report of brucella and COVID-19 coinfection.

It is expected that COVID-19 may obscure or mimic other febrile illness in endemic areas. The presence of SARS-COV may not be taken as an indication of the absence of other infections when the presentation is atypical, or the history suggests an alternative or additional diagnosis. "COVID-19 mimic" has been described where an elderly patient admitted with a fall tested J o u r n a l P r e -p r o o f positive for SARS-CoV-2, while another patient was referred to the ER as a COVID-19 patient and found to have CHF. The test for SARS-COV was repeatedly negative in this patient. [17] In conclusion, physicians should have a high index of suspicion for SARS-COV infection and should exclude this diagnosis, especially in admitted patients. This is crucial to interrupt the transmission cycle of this virus. Similarly, other endemic diseases should not be overlooked in COVID-19 patients since SARS-CoV-2 might be a bystander and many of these patients could be asymptomatic.

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish the case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. none none Consent is obtained J o u r n a l P r e -p r o o f

Please specify the contribution of each author to the paper, e.g. study design, data collections, data analysis, writing, others, who have contributed in other ways should be listed as contributors.

F Elzein wrote the manuscript and followed the patient. N AlSherbeeni followed the patient and critically reviewed the manuscript, Kaabia . Kholoud Almatrafi , and Diaa Shosha collected information from the patient and followed the lab results. Both critically reviewed the manuscript

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR

Brucellosis and the Respiratory System

Brucellosis and the gastrointestinal tract: The odd couple

Covid-net LCD. Hospitalization Rates and Characteristics of Patients Hospitalized with

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCRbased case-control study. Short running title: chemosensory disorders in Covid-19

Hunter's

COVID-19 and pets: When pandemic meets panic

Zoonotic origins of human coronaviruses

COVID 19 and mycoplasma pneumoniae coinfection

Coinfection between dengue and covid-19: need for approach in endemic zones

Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Mimics and chameleons of COVID-19